Inhibitors of the fibroblast growth factor receptor
US-2015197519-A1 · Jul 16, 2015 · US
Bicyclic heterocycles as FGFR inhibitors
US9533984B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9533984-B2 |
| Application number | US-201414256438-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2014 |
| Priority date | Apr 19, 2013 |
| Publication date | Jan 3, 2017 |
| Grant date | Jan 3, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is: 2′-(2,6-difluoro-3,5-dimethoxyphenyl)-6′-[(2-morpholin-4-ylethyl)amino]-1′,2′-dihydro-3′H-spiro[cyclopropane-1,4′-[2,4]naphthyridin]-3′-one or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. 3. A compound which is 2′-( 2 , 6 -difluoro- 3 , 5 -dimethoxyphenyl)- 6 ′-[(2-morpholin-4-ylethyl)amino]-1′,2′-dihydro-3′H-spiro]cyclopropane-1,4′-[2,7]naphthyridin]-3′-one. 4. A pharmaceutical composition comprising the compound of claim 3 and at least one pharmaceutically acceptable carrier or excipient. 5. A pharmaceutically acceptable salt of 2′-(2,6-difluoro-3,5-dimethoxyphenyl) -6′-[(2-morpholin-4-ylethyl)amino]-1′,2′-dihydro-3′H -spiro[cyclopropane-1,4′-[2,7]naphthyridin]-3′-one. 6. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 5 , and at least one pharmaceutically accceptable carrier or excipient.
Assignees
Inventors
Classifications
- C07D471/04Primary
Ortho-condensed systems · CPC title
Antineoplastic agents · CPC title
- A61K31/4375Primary
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9533984B2 cover?
- The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
- Who is the assignee on this patent?
- Incyte Corp, Incyte Holdings Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).